XML 19 R6.htm IDEA: XBRL DOCUMENT v3.3.1.900
Statements of Cash Flows - USD ($)
 6 Months Ended 12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Jun. 30, 2015
Jun. 30, 2014
Cash flows from operating activities        
Net loss $ (5,608,568) $ (3,725,772) $ (7,723,404) $ (5,578,690)
Stock-based compensation expense 250,887 477,660 1,017,938 499,690
Depreciation, amortization and accretion 242,427 49,164 118,202 97,476
Amoritzation of debt issuance costs 147,805 0    
Derivative expense 78,038 0    
Amortization of prepaid research and development - related party 60,991 60,992 121,984 35,579
Deferred taxes 0 (23,910) (23,910) (813,697)
Adjustments to reconcile net loss to net cash used in operating activities:        
(Increase) in accounts receivable (131,408) (6,906) (157,058) 0
(Increase) in inventory (613,673) (10,453) (39,442) 0
(Increase) decrease in prepaid expenses, other (370,656) 485,889 150,434 (497,322)
(Increase) in prepaid research and development - related party 0 (150,000) (150,000) (465,000)
(Decrease) in accounts payable and accrued liabilities (126,781) (298,677)    
Increase in accounts payable 38,451 (561,059) 547,314 421,870
Increase in accrued compensation 296,081 94,247 196,503 0
(Decrease) increase in interest payable to Ampio 161,988 74,936 (46,002) 46,002
(Decrease) in payable to Ampio     (561,059) 561,059
Increase in deferred rent 10,245 0    
(Decrease) increase in deferred revenue (42,857) (42,858) (85,714) 191,071
Net cash used in operating activities (5,607,030) (3,576,747) (6,634,214) (5,501,962)
Cash flows used in investing activities        
Deposits 1,998 (1,998) (4,886) 0
Purchase of ProstaScint Business (540,000) 0 (1,000,000) 0
Purchases of fixed assets (125,161) 0 0 (9,298)
Net cash used in investing activities (663,163) (1,998) (1,004,886) (9,298)
Cash flows from financing activities        
Ampio stock subscription payment 5,000,000 0 5,000,000 0
Proceeds from convertible promissory notes, net 5,175,000 0 7,400,000 4,600,000
Luoxis option payout pursuant to the merger     (27,476) 0
Liabilities paid out pursuant to the merger     (20,013) 0
Contribution from Ampio 0 1,100,000 0 637,210
Debt issuance costs (Note 8) (298,322)      
Net cash provided by financing activities 9,876,678 1,100,000 12,352,511 5,237,210
Net change in cash and cash equivalents 3,606,485 (2,478,745) 4,713,411 (274,050)
Cash and cash equivalents at beginning of period 7,353,061 2,639,650 2,639,650 2,913,700
Cash and cash equivalents at end of period 10,959,546 160,905 7,353,061 2,639,650
Non-cash transactions:        
Ampio stock subscription     5,000,000 0
Ampio unpaid debt converted to stock, received prior to 2015     4,600,000 0
Contingent consideration related to the ProstaScint purchase     664,000 0
Issuance of common stock in exchange for Vyrix acquired assets     0 6,803,356
Related party research and development liability included in prepaid research and development - related party     $ 0 $ 150,000
Warrant derivative liability related to the issuance of the convertible promissory notes (Note 8) 102,931 0    
Primsol business purchase included in primsol payable, $1,250,000 less future accretion of $173,000 1,077,000 0    
Fixed asset purchases included in accounts payable $ 7,708 $ 0